News

Data from PREEMPT CRC reveal the blood-based screening test demonstrated a 79.2% sensitivity for detecting colorectal cancer.

At the end of the study period, the median dose of daprodustat and ESA were higher among the ESA-HR cohort when compared with the non-ESA-HR group.

A detailed overview and accompanying quiz on the recommendations made by the AGA in their 2024 guideline on endoscopic eradication

End-of-study results from the phase 3 REGENERATE study were presented at DDW and highlight obeticholic acid’s trend in benefit for clinical outcomes.

Both doses of guselkumab exhibited statistical superiority on all prespecified pooled endoscopic endpoints versus ustekinumab in Crohn's disease.

New STARS data were presented in a late-breaking abstract at DDW and build upon positive topline results for clinical responder rates and reductions in parenteral support.

Arthroscopic approach with augmentation of the labrum repair has resulted in complete restoration of shoulder function and a permanent stop to dislocations.

Feuerstadt breaks down findings from an ad hoc analysis of PUNCH CD3 and what the results suggest about the use of live-jslm (Rebyota) in patients taking concomitant medications.

During follow-up, rates of incident PAD were higher among patients with depressive symptoms compared with those without depression.

An assessment to improve colorectal screenings by shipping Cologuard kits to non-compliant patients proved beneficial for a Mayo Clinic research team.

These late-breaking data on drug candidate ENV-101 were presented at ATS 2024 and resulted from a new study on the drug’s effect on individuals with IPF.

James R. Kilgore, DMSc, PhD, PA-C, discusses a new primary care screening tool for cognitive decline, plus lifestyle interventions that may complement drugs.

Beth Browning, PA-C, LPC, provides advice for busy primary care providers to efficiently incorporate timely and treatment-initiating depression screening.

On May 20, 2024, the FDA announced the approval of 2 products as interchangeable biosimilars to aflibercept—the first products to receive such a designation from the FDA.

The phase 3 QUASAR Maintenance study met its primary endpoint of clinical remission and demonstrated statistically significant endoscopic remission rates in UC treatment.

Sehgal explains the safety and efficacy of GLP-1RAs in patients with IBD as well as the impact on inflammatory biomarkers.

A numerically slower decline in eGFR was reported in the finerenone cohort after hospitalization for heart failure when compared with placebo.

Damas explains key findings from her pilot study exploring intervals of a low-calorie plant-based diet as adjunctive therapy to medication in patients with ulcerative colitis.

Use of dupilumab reduced exacerbations and improved lung function in COPD patients with type 2 inflammation.

Rezaie describes recent trends in GLP-1RA prescription patterns from his population-based research presented at DDW, highlighting increases in off-label use.

Fortman reviews the state of the 2021 AHA/ACC guideline recommendations to pursue shared decision making and cost-efficient testing strategies.

More than half of patients recruited for this research showed improvements in wound healing, and a significant number had greater wound stability.

Dolinger reviews findings from his research presented at DDW about the use of intestinal ultrasound response for predicting endoscopic outcomes in children with UC.

Kilgore reviews early cognitive decline tools include AD8 and MoCA, and how they should be utilized at the primary care level.

TNF-α levels in the sweat correlate with serum values in patients with IBD, suggesting the wearable's feasibility in non-invasive disease monitoring.

Bludorn reviews preventive measures and strategic collaboration to ensure high-risk patients for conditions like heat stroke are identified before an acute event occurs.

An AAPA 2024 session reflected on the joint AHA/ACC chest pain guidelines, particularly the adoption of high-density troponin level testing since 2021.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on the role of advocacy and patient voice in HBV management.